Arovella Therapeutics Limited

Arovella Therapeutics Limited, a biotechnology company develops therapies for the treatment of cancer in Australia and globally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias.

Its portfolio also includes ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer, and IL-12-TM for treating solid tumors.

Formerly known as Suda Pharmaceuticals Ltd, the company rebranded as Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia.